brivaracetam / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 24 Diseases   12 Trials   12 Trials   871 News 


12345678910111213»
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
    Review, Journal, Adverse events:  SERIOUS ADVERSE EFFECTS of SELECTED ANTISEIZURE MEDICATIONS USED for TREATMENT of FOCAL ONSET SEIZURES. (Pubmed Central) -  Dec 23, 2024   
    Lacosamide is associated with rhythm and conduction disturbances in the myocardium, so caution and ECG monitoring are required in people with cardiac diseases. Eslicarbazepine, cenobamate, and lacosamide can cause Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome and other allergic manifestations, so they should be used with caution in people with allergies in medical history.
  • ||||||||||  phenytoin / Generic mfg.
    Journal:  The Phenytoin Ataxia Enigma Unveiled ''A Case Report''. (Pubmed Central) -  Dec 12, 2024   
    Case: Herein, we present a case report of a 16-year-old Asian patient with a past history of epilepsy that was admitted to a tertiary care hospital due to the development of ataxia, giddiness, and vomiting when taking Phenytoin in addition to Oxcarbazepine, Clobazam, and Levetiracetam to treat seizures...Thus, the Phenytoin drug was discontinued in the patient gradually and he was continued on clobazam, oxcarbazepine, and brivaracetam which led to reversal of the ADR in the patient...Given the scarcity of ataxia cases caused by Phenytoin, awareness is lacking within the scientific community. Our aim is to provide insights to promote better monitoring and patient-centered treatment outcomes for epileptic patients.
  • ||||||||||  brivaracetam / Generic mfg.
    Retrospective data, Journal, Monotherapy:  BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice. (Pubmed Central) -  Dec 11, 2024   
    In our study, monotherapy with BRV reduced seizures in patients who had not received other treatments and in patients who switched from a previous treatment to BRV monotherapy. BRV was well tolerated and also effective in sensitive patients (i.e., the elderly and those who had epilepsy caused by a brain tumor or a brain injury).
  • ||||||||||  levetiracetam / Generic mfg., brivaracetam / Generic mfg.
    Transitioning from Levetiracetam to Brivaracetam in Veterans with Medically Refractory Epilepsy (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2553;    
    While, generally, in adult populations, the incidence of BAEs is estimated at 13.3% of patients on LEV, only 4.35% of veterans at our institution were switched from LEV to BRV. In veterans with BAEs on LEV, switching to BRV was associated with a reduction in BAEs.
  • ||||||||||  lacosamide / Generic mfg., pregabalin / Generic mfg., brivaracetam / Generic mfg.
    Monitoring Anti-seizure Medication Efficacy with Sub-scalp EEG (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2296;    
    P
    Large deviations in expected residual values indicate a change in seizure rate due ASM. A non-sustained change in residuals is an early indicator of ineffective ASM, flagging the need to try another therapy.
  • ||||||||||  levetiracetam / Generic mfg., brivaracetam / Generic mfg.
    Microsampling Methodology to Allow Self-collection of Blood in Pharmacokinetic Studies (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_2290;    
    A non-sustained change in residuals is an early indicator of ineffective ASM, flagging the need to try another therapy. To facilitate convenient self-collection of pharmacokinetic study samples and reduce the necessity for in-person study, we developed and validated a robust microsampling assay to measure the concentrations of three ASMs - levetiracetam (LEV), lamotrigine (LTG), and brivaracetam (BRV)
  • ||||||||||  Xcopri (cenobamate) / SK Bio
    The Fruit Fly Drosophila Melanogaster as a Screening Tool for Antiseizure Medications (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1954;    
    These findings further demonstrate the usability of Drosophila for assaying drugs with antiseizure properties. Next, the same ASMs will be tested in another bang-sensitive mutant (paralyticbss1) that serves as a model for intractable epilepsy.
  • ||||||||||  A Novel Deletion in NEXMIF Is Associated with Continuous Spike-wave During Slow-wave Sleep (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1454;    
    Patients with NEXMIF-related epilepsy must be evaluated for underlying CSWS, particularly in cases of medically refractory seizures, status epilepticus, or cognitive deterioration. Long-term EEG monitoring should be considered since routine EEG can be of low yield to detect CSWS.
  • ||||||||||  dalfampridine / Generic mfg.
    Use of 4-aminopyridine in KCNA2 Epilepsy and Neurodevelopmental Disorder (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1394;    
    Whole genome sequencing identified a de novo pathogenic variant in KCNA2 (c.890G >A, p.(Arg297Gln), CGG >CAG in exon 3, NM_004974.3), consistent with a GOF mutation associated with KCNA2-related epilepsy and neurodevelopmental disorder type 32. A total of 15 patients with an identical genomic variant to our patient have been reported
  • ||||||||||  Fintepla (low-dose fenfluramine) / UCB
    Reviving Fenfluramine: A New Hope for Pediatric Apneic Seizures in SMC1A Mutations (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1341;    
    This case study reaffirms FFA's potential as a seizure treatment in pediatric neurology, particularly for patients with SMC1A mutations with apneic seizure, and underlines the imperative for further investigative efforts in this subgroup. Furthermore, the drastic reduction in apneic seizure frequency in this patient emphasized FFA's specific potential in preventing long-term hypoxic brain injury.
  • ||||||||||  Do Physicians Use New Asms in Order of Approval? (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1093;    
    In addition, Brivaracetam was trialed ahead of ASMs in the early group most often, possibly due to its earlier release date and the fact that Epidiolex is not approved for focal epilepsy. The more recently approved ASMs were used before Perampanel and Eslicarbazepine more than 63% and 75% of the time, respectively, suggesting that clinicians had more optimism about the newer ASMs than these older ones.
  • ||||||||||  Xcopri (cenobamate) / SK Bio
    Cenobamate-associated Weight Loss (CENOBAWEIGHT Study) (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_1007;    
    A comprehensive review at one center reveals that 12 out of 191 patients experienced weight loss of greater than 10% attributable to cenobamate, with most patients at a dose of at least 200mg. In our cohort, the effect was reversible with minor dose reduction.
  • ||||||||||  Kineret (anakinra) / SOBI
    A 16-year-old Girl with Recurrent Refractory Status Epilepticus Post Recovery from NORSE (South Hall H - Level 1 - LACC) -  Nov 26, 2024 - Abstract #AES2024AES_842;    
    The patient's hospital course included severe complications, emphasizing the need for further research to better understand the mechanism and effective treatment strategy. The use of cytokine panels and genetic testing has potential to customize management, guide future research and therapeutic targets.
  • ||||||||||  brivaracetam / Generic mfg.
    Enrollment closed, Trial primary completion date:  Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (clinicaltrials.gov) -  Oct 17, 2024   
    P3,  N=40, Active, not recruiting, 
    Based on our outcomes, this dual therapy provides supporting evidence in alleviating epilepsy-induced neurobehavioral comorbidities and changes in redox homeostasis. Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2028 --> Aug 2024
  • ||||||||||  brivaracetam / Generic mfg.
    Clinical, Retrospective data, Journal:  Brivaracetam use in children with epilepsy: A retrospective multicenter study. (Pubmed Central) -  Oct 6, 2024   
    Approximately one-fifth of pediatric patients with drug-resistant epilepsy responded to BRV, with the best response observed in patients with focal seizures. However, the impact on patients with epileptic encephalopathy was limited.
  • ||||||||||  Xcopri (cenobamate) / SK Bio
    Clinical, Retrospective data, Journal, Real-world evidence, Real-world:  Cenobamate: real-world data from a retrospective multicenter study. (Pubmed Central) -  Oct 2, 2024   
    However, the impact on patients with epileptic encephalopathy was limited. CNB proved to be a highly effective and generally well-tolerated ASM in patients with severe drug-resistant epilepsy, comprising a broad array of epilepsy syndromes beyond focal epilepsy.
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma
    Preclinical, Journal:  A single exposure to brivaracetam or perampanel does not cause cell death in neonatal rats. (Pubmed Central) -  Oct 1, 2024   
    By contrast, neither BRV nor PER increased the number of pathogreen positive cells in any region examined. Our results suggest that BRV and PER may have a positive safety profile-at least with respect to acute induction of cell death - and therefore may offer a safer option for the treatment of early life seizures.
  • ||||||||||  brivaracetam / Generic mfg.
    Trial completion:  Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury (clinicaltrials.gov) -  Sep 27, 2024   
    P1/2,  N=24, Completed, 
    Our results suggest that BRV and PER may have a positive safety profile-at least with respect to acute induction of cell death - and therefore may offer a safer option for the treatment of early life seizures. Active, not recruiting --> Completed
  • ||||||||||  Review, Journal:  Advances in the chemoenzymatic synthesis of gamma-aminobutyric acid derivatives (Pubmed Central) -  Sep 25, 2024   
    This article reviews the latest advances in the chemical synthesis and chemoenzymatic synthesis of GABA derivatives. Furthermore, it introduces the progress in the industrial synthesis of representative GABA derivatives such as gabapentin, pregabalin, and brivaracetam and prospects the future development of GABA derivatives.
  • ||||||||||  brivaracetam / Generic mfg.
    Trial primary completion date:  EHAD: Epileptic Hippocampus in Alzheimer's Disease (clinicaltrials.gov) -  Sep 25, 2024   
    P1/2,  N=25, Not yet recruiting, 
    Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025 Trial primary completion date: Jun 2028 --> Jun 2029
  • ||||||||||  levetiracetam / Generic mfg., brivaracetam / Generic mfg.
    Journal:  Ru-Catalyzed Asymmetric Hydrogenation of ?,?-Unsaturated ?-Lactams. (Pubmed Central) -  Sep 2, 2024   
    Mechanistic studies based on detailed control experiments and computational investigation revealed that the cationic Ru-complex acts as the active catalytic species; the protonation process of the oxa-?-allyl-Ru complex, which is formed by the migratory insertion of the C=C double bond to the Ru-H bond (the stereocontrolling step) followed by an isomerization process, is the rate-determining step, and the existence of PPh3 is crucial for the highly efficient catalytic behavior. The protocol provides a straightforward and practical pathway for the synthesis of key intermediates for several chiral drugs and bioactive compounds, particularly for the 150 kg-scale industrial production of Brivaracetam, an antiepileptic drug that shows 13-fold more potent binding to the synaptic vesicle protein 2A compared with the well-known Levetiracetam.